BioPharmSignal logoBioPharmSignal

Biotech News

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

Nurix Therapeutics (NRIX)Nurix TherapeuticsClinical readout

Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive approximately $453 million in future milestones associated with the STAT6 program, as well

Related news

NRIXNurix Therapeutics2026-10-07 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

KYMRKymera2026-09-01 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

REGNRegeneron Pharmaceuticals2026-10-06 11:00 EST

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

REGNRegeneron Pharmaceuticals2026-10-01 15:30 EST

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

GPCRStructure Therapeutics2026-09-08 12:00 EST

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

RVMDRevolution Medicines2026-09-02 21:50 EST

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

RVMDRevolution Medicines2026-10-05 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

FATEFate Therapeutics2026-09-25 11:00 EST

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

View all latest news

Nurix Therapeutics

Targeted Protein Degradation Nurix Therapeutics develops medicines that use the cell’s ubiquitin-proteasome system to remove disease-causing proteins. Its portfolio includes wholly owned degraders and programs partnered with large pharmaceutical companies. Bexobrutideg Bexobrutideg is an oral BTK degrader being advanced as a potential...

Recent company news

NRIXNurix Therapeutics2026-10-07 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

NRIXNurix Therapeutics2026-09-01 12:00 EST

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

Stock data

Close
22.60 USD
Market cap
1.69B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States